CLICK TO SHARE
Shaun Chilton has been the CEO of Clinigen Group plc (LON:CLIN) since 2016, and this article will examine the executive's compensation with respect to the overall performance of the company. This analysis will also look to assess whether the CEO is appropriately paid, considering recent earnings growth and investor returns for Clinigen Group.
Our data indicates that Clinigen Group plc has a market capitalization of UK£758m, and total annual CEO compensation was reported as UK£1.5m for the year to June 2020. That's a notable decrease of 42% on last year. We think total compensation is more important but our data shows that the CEO salary is lower, at UK£600k.
On comparing similar companies from the same industry with market caps ranging from UK£307m to UK£1.2b, we found that the median CEO total compensation was UK£2.6m. In other words, Clinigen Group pays its CEO lower than the industry median. Furthermore, Shaun Chilton directly owns UK£1.9m worth of shares in the company.
On an industry level, around 49% of total compensation represents salary and 51% is other remuneration. Clinigen Group sets aside a smaller share of compensation for salary, in comparison to the overall industry. If non-salary compensation dominates total pay, it's an indicator that the executive's salary is tied to company performance.
Clinigen Group plc has seen its earnings per share (EPS) increase by 46% a year over the past three years. In the last year, its revenue is up 10%.
If you don't see any comments yet, congrats! You get first comment. Be nice and have fun.
CLICK TO SHARE